Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)

Completed

Conditions studied: Mucopolysaccharidosis (MPS), Hunter Syndrome

In brief

Hunter syndrome (Mucopolysaccharidosis II, \[MPS II\]) is a rare, genetically linked lysosomal storage disease (LSD) caused by deficiency of the enzyme, iduronate-2-sulfatase (I2S). Most MPS II patients will present with some degree of neurodevelopmental involvement, ranging from severe cognitive impairment and behavioral problems to mildly impaired cognition. This is an observational study; no investigational treatment will be administered. The primary objective of this study is to evaluate the neurodevelopmental status of pediatric patients with MPS II over time and to gain information to guide future treatment studies in this patient population.

Key facts

Study ID

NCT01822184

Run by

Shire

People needed

100

Starts

2013-01-18

Expected to finish

2016-10-05

Last updated by the study team

2021-03-17

Who can join

Age: 2 and older, up to 18. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet all of the following criteria to be considered eligible for enrollment:
• a. The patient has a deficiency in iduronate-2-sulfatase enzyme activity AND b. The patient has a documented mutation in the iduronate-2-sulfatase gene. OR c. The patient has a normal enzyme activity level of one other sulfatase
• The patient is male, and is at least 2 years of age and less than 18 years of age at the time of informed consent.
• The patient must have sufficient auditory capacity at enrollment, with or without hearing aids, in the Investigator's judgment to complete the required protocol testing, and be compliant with wearing the aids on scheduled study visits.
• The patient, patient's parent(s), or legally authorized guardian(s) has voluntarily signed an Institutional Review Board / Independent Ethics Committee-approved informed consent and/or assent form(s), as applicable.

You may not qualify if…

• Patients who meet any of the following criteria will be excluded from the study.
• The patient has clinically significant non-Hunter syndrome-related CNS involvement or medical or psychiatric comorbidity(ies) which, in the investigator's judgment, may interfere with the accurate administration and interpretation of protocol assessments, affect study data, or confound the integrity of study results.
• The patient has a general conceptual ability score (GCA) or a developmental quotient on the cognitive scale below 55 at Screening.
• The patient is participating in an interventional clinical trial or has participated in an interventional clinical trial within 30 days prior to enrollment; participation in non interventional observational studies is permitted.

Where it is running

• Childrens Hospital & Research Center Oakland — Oakland, California, United States
• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States
• University of North Carolina Division of Genetics and Metabolism — Chapel Hill, North Carolina, United States
• Hospital Universitario Austral — Pilar, Buenos Aires, Argentina
• Instituto Nacional De Pediatria — Mexico City, Mexico
• Hospital Infantil Universitario — Madrid, Spain
• Central Manchester University Hospitals NHS Foundation Trust Willink Biochemical Genetics Unit, St. Mary's Hospital — Manchester, M13 9WL, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.